Predicted contributions of cytochrome P450s to drug metabolism in human liver microsomes using relative activity factor were dependent on probes

References

• Crewe HK, Barter EZ, Yeo RK, et al. (2011). Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. Biopharm Drug Dispos 32:303–18.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu L, Nguyen K, et al. (2011). Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450. Drug Metab Dispos 39:373–82.
   PubMed Web of Science ®Google Scholar
• Crespi CL. (1995). Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:170–235.
   Google Scholar
• Crespi CL, Miller VP. (1999). The use of heterologously expressed drug metabolizing enzymes—state of the art and prospects for the future. Pharmacol Ther 84:121–31.
   PubMed Web of Science ®Google Scholar
• Dambro MR, Kallgren MA. (1988). Drug interactions in a clinic using COSTAR. Comput Biol Med 18:31–8.
   PubMed Web of Science ®Google Scholar
• Draper AJ, Madan A, Latham J, et al. (1998). Development of a non-high pressure liquid chromatography assay to determine [14C]chlorzoxazone 6-hydroxylase (CYP2E1) activity in human liver microsomes. Drug Metab Dispos 26:305–12.
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Hustert E, et al. (2004). Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 60:231–6.
   PubMed Web of Science ®Google Scholar
• El-Bagary RI, Elkady EF, El-Sherif ZA, et al. (2014). LC-MS-MS simultaneous determination of atorvastatin and ezetimibe in human plasma [J]. J Chromatogr Sci 52:773–80.
   PubMed Web of Science ®Google Scholar
• Galetin A, Clarke SE, Houston JB, et al. (2001). Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone and nifedipine. Drug Metab Dispos 31:1108–16.
   Web of Science ®Google Scholar
• Guengerich FP. (2006). Cytochrome P450s and other enzymes in drug metabolism and toxicity. ASPS J. 8:E101–11.
   Google Scholar
• Houston JB, Kenworthy KE. (2000). In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246–54.
   PubMed Web of Science ®Google Scholar
• Hu N, Xie S, Liu L, et al. (2010). Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos 39:419–25.
   PubMed Web of Science ®Google Scholar
• Jacobsen W, Kuhn B, Soldner A, et al. (2000). Lactoni Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 28:1369–78.
   PubMed Web of Science ®Google Scholar
• Jia L, Zhong Z, Li F, et al. (2014). The aggravation of clozapine-induced hepatotoxicity by glycyrrhetinic acid in rats. J Pharmacol Sci 124:468–79.
   PubMed Web of Science ®Google Scholar
• Jornil J, Jensen KG, Larsen F, et al. (2010). Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos 38:376–85.
   PubMed Web of Science ®Google Scholar
• Kenworthy KE, Bloomer JC, Clarke SE, et al. (1999). CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716–27.
   PubMed Web of Science ®Google Scholar
• Kumar V, Rock DA, Warren CJ, et al. (2006a). Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos 34:1903–8.
   PubMed Web of Science ®Google Scholar
• Kumar V, Wahlstrom JL, Rock DA, et al. (2006b). CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966–75.
   PubMed Web of Science ®Google Scholar
• Lin YS, Dowling AL, Quigley SD, et al. (2002). Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162–72.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Nakamura S, Tokudome S, et al. (1999). Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 27:1381–91.
   PubMed Web of Science ®Google Scholar
• Ohyama K, Murayama N, Shimizu M, et al. (2014). Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. Xenobiotica 44:10–16.
   PubMed Web of Science ®Google Scholar
• Perloff MD, von Moltke LL, Court MH, et al. (2000). Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618–28.
   PubMed Web of Science ®Google Scholar
• Roy P, Yu LJ, Crespi CL, et al. (1999). Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655–66.
   PubMed Web of Science ®Google Scholar
• Siu YA, Lai WG. (2017). Impact of probe substrate selection on cytochrome P450 reaction phenotyping using the relative activity factor. Drug Metab Dispos 45:183–9.
   PubMed Web of Science ®Google Scholar
• Soars MG, Gelboin HV, Krausz KW, et al. (2003). A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology [J]. Br J Clin Pharmacol 55:175–81.
   PubMed Web of Science ®Google Scholar
• Spatzenegger M, Jaeger W. (1995). Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27:397–417.
   PubMed Web of Science ®Google Scholar
• Tseng E, Walsky RL, Luzietti RA Jr, et al. (2014). Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide). Drug Metab Dispos 42:1163–73.
   PubMed Web of Science ®Google Scholar
• Tang X, Di X, Zhong Z, et al. (2016). In vitro metabolism of l-corydalmine, a potent analgesic drug, in human, cynomolgus monkey, beagle dog, rat and mouse liver microsomes. J Pharm Biomed Anal 128:98–105.
   PubMed Web of Science ®Google Scholar
• Toshiyuki T, Tomonori K, Ryuichi M, et al. (2007). Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies. Drug Metab Pharmacokinet 22:409–18.
   PubMed Web of Science ®Google Scholar
• Tracy ST, Hutzler JM, Haining RL, et al. (2002). Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the f144l active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 30:385–90.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–60.
   PubMed Web of Science ®Google Scholar
• Wang D, Liang Y, Chen W, et al. (2008). Identification of ginkgolide B metabolites in urine and rat liver cytochrome P450 enzymes responsible for their formation in vitro. Acta Pharmacol Sin 29:376–84.
   PubMed Web of Science ®Google Scholar
• Wang JS, Neuvonen M, Wen X, et al. (2002). Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352–6.
   PubMed Web of Science ®Google Scholar
• Weaver ML, Orwig BA, Rodriguez LC, et al. (2001). Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 29:415–21.
   PubMed Web of Science ®Google Scholar
• Wink CS, Meyer GM, Meyer MR, et al. (2015). Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps ]. Toxicol Lett 238:39–44.
   PubMed Web of Science ®Google Scholar
• Xie Q, Chen Y, Liu F, et al. (2016). Interspecies differences in metabolism of deoxypodophyllotoxin in hepatic microsomes from human, monkey, rat, mouse and dog. Drug Metab Pharmacokinet 31:314–22.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang J, Li W, et al. (2014). In vitro metabolism of 20(R)-25-methoxyl-dammarane-3, 12, 20-triol from Panax notoginseng in human, monkey, dog, rat, and mouse liver microsomes. PLoS One 9:e94962.
   PubMed Web of Science ®Google Scholar
• Zhao XP, Zhong J, Liu XQ, et al. (2007). CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes. Acta Pharmacol Sin 28:118–24.
   PubMed Web of Science ®Google Scholar